The Impact of Postoperative Tumor Burden on Patients With Brain Metastases.
brain metastasis
extent of resection (EOR)
neuro-oncology
overall survival (OS)
postoperative MRI
tumor burden
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2022
2022
Historique:
received:
05
02
2022
accepted:
24
03
2022
entrez:
23
5
2022
pubmed:
24
5
2022
medline:
24
5
2022
Statut:
epublish
Résumé
Brain metastases were considered to be well-defined lesions, but recent research points to infiltrating behavior. Impact of postoperative residual tumor burden (RTB) and extent of resection are still not defined enough. Adult patients with surgery of brain metastases between April 2007 and January 2020 were analyzed. Early postoperative MRI (<72 h) was used to segment RTB. Survival analysis was performed and cutoff values for RTB were revealed. Separate (subgroup) analyses regarding postoperative radiotherapy, age, and histopathological entities were performed. A total of 704 patients were included. Complete cytoreduction was achieved in 487/704 (69.2%) patients, median preoperative tumor burden was 12.4 cm RTB is a strong predictor for survival. Maximal cytoreduction, as confirmed by postoperative MRI, should be achieved whenever possible, regardless of type of postoperative radiotherapy.
Sections du résumé
Background
UNASSIGNED
Brain metastases were considered to be well-defined lesions, but recent research points to infiltrating behavior. Impact of postoperative residual tumor burden (RTB) and extent of resection are still not defined enough.
Patients and Methods
UNASSIGNED
Adult patients with surgery of brain metastases between April 2007 and January 2020 were analyzed. Early postoperative MRI (<72 h) was used to segment RTB. Survival analysis was performed and cutoff values for RTB were revealed. Separate (subgroup) analyses regarding postoperative radiotherapy, age, and histopathological entities were performed.
Results
UNASSIGNED
A total of 704 patients were included. Complete cytoreduction was achieved in 487/704 (69.2%) patients, median preoperative tumor burden was 12.4 cm
Conclusions
UNASSIGNED
RTB is a strong predictor for survival. Maximal cytoreduction, as confirmed by postoperative MRI, should be achieved whenever possible, regardless of type of postoperative radiotherapy.
Identifiants
pubmed: 35600394
doi: 10.3389/fonc.2022.869764
pmc: PMC9114705
doi:
Types de publication
Journal Article
Langues
eng
Pagination
869764Informations de copyright
Copyright © 2022 Aftahy, Barz, Lange, Baumgart, Thunstedt, Eller, Wiestler, Bernhardt, Combs, Jost, Delbridge, Liesche-Starnecker, Meyer and Gempt.
Déclaration de conflit d'intérêts
JG and BM work as consultants for Brainlab (Brainlab AG, Feldkirchen). In addition, BM works as consultant for Medtronic, Spineart, Icotec, Relievant, and Depuy/Synthes. In these firms, BM acts as a member of the advisory board. Furthermore, BM reports a financial relationship with Medtronic, Ulrich Medical, Brainlab, Spineart, Icotec, Relievant, and Depuy/Synthes. He received personal fees and research grants for clinical studies from Medtronic, Ulrich Medical, Brainlab, Icotec, and Relievant. All this happened independently of the submitted work. BM holds the royalties/patent for Spineart. PJ has had a consulting or advisory role, and received honoraria, research funding, and/or travel/accommodation expenses from Ariad, Abbvie, Bayer, Boehringer, Novartis, Pfizer, Servier, Roche, BMS and Celgene, Pierre Fabre, Janssen/Johnson & Johnson, and MSD. All named potential conflicts of interest are unrelated to this study. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Lancet Oncol. 2006 May;7(5):392-401
pubmed: 16648043
J Neurosurg. 2012 Nov;117(5):851-9
pubmed: 22978537
Cancers (Basel). 2019 Mar 01;11(3):
pubmed: 30832257
Acta Neurochir (Wien). 2013 Mar;155(3):379-87
pubmed: 23314988
J Neurosurg. 2001 Aug;95(2):190-8
pubmed: 11780887
Neurosurgery. 2009 Apr;64(4):664-74; discussion 674-6
pubmed: 19197219
Neurosurgery. 2008 Mar;62(3):564-76; discussion 564-76
pubmed: 18425006
J Neurosurg. 2010 Aug;113(2):181-9
pubmed: 20035574
Sci Rep. 2021 Jan 12;11(1):695
pubmed: 33436737
Curr Opin Neurol. 2009 Dec;22(6):645-9
pubmed: 19738467
Front Oncol. 2020 May 08;10:693
pubmed: 32477942
J Clin Oncol. 2006 Mar 10;24(8):1289-94
pubmed: 16525184
Neuro Oncol. 2017 Feb 1;19(2):162-174
pubmed: 28391295
Neuro Oncol. 2014 Jan;16(1):113-22
pubmed: 24285550
Curr Oncol. 2020 Feb;27(1):39-45
pubmed: 32218659
J Neurosurg. 2018 Dec 1;:1-8
pubmed: 30554174
JAMA. 2013 Nov 27;310(20):2191-4
pubmed: 24141714
Sci Rep. 2019 May 15;9(1):7431
pubmed: 31092876
Lancet Oncol. 2017 Aug;18(8):1040-1048
pubmed: 28687375
J Clin Oncol. 2015 Oct 20;33(30):3475-84
pubmed: 26282648
Acta Neurochir (Wien). 2015 Sep;157(9):1573-80
pubmed: 26156037
Acta Neurochir (Wien). 2019 Mar;161(3):555-565
pubmed: 30756241
J Neurosurg. 2008 Feb;108(2):248-57
pubmed: 18240919
BMC Cancer. 2020 May 12;20(1):410
pubmed: 32398144
Lancet Oncol. 2011 Oct;12(11):997-1003
pubmed: 21868284
JAMA Oncol. 2020 Dec 01;6(12):1901-1909
pubmed: 33057566
J Neurosurg. 2011 Jul;115(1):3-8
pubmed: 21417701
Lancet Oncol. 2015 Jun;16(6):e270-8
pubmed: 26065612
J Clin Oncol. 2011 Jan 10;29(2):134-41
pubmed: 21041710
Lancet Oncol. 2017 Aug;18(8):1049-1060
pubmed: 28687377
J Neurosurg. 2015 May;122(5):1132-43
pubmed: 25794344
J Neurooncol. 2009 May;92(3):275-82
pubmed: 19357955
Neuro Oncol. 2013 Dec;15(12):1664-72
pubmed: 24084410
J Neurooncol. 2018 Sep;139(2):449-454
pubmed: 29749569
JAMA. 1998 Nov 4;280(17):1485-9
pubmed: 9809728
Neurosurgery. 1994 Jan;34(1):45-60; discussion 60-1
pubmed: 8121569
PLoS One. 2014 Feb 24;9(2):e89389
pubmed: 24586742
Cancer. 1994 Sep 15;74(6):1784-91
pubmed: 8082081
Neurooncol Adv. 2020 Jan-Dec;2(1):vdaa041
pubmed: 32363344
JAMA Oncol. 2020 Apr 1;6(4):495-503
pubmed: 32027343